Avid prepares to present findings of Alzheimer's study

06/23/2010 | New York Times (tiered subscription model), The

Avid Radiopharmaceuticals, a company that developed fluoride 18-based dyes for use in PET scans of amyloid plaques, said it has received the results of a study using its dye to determine whether Alzheimer's disease diagnosed through a PET scan correlates with that determined through a brain autopsy. The results, to be presented at the Alzheimer's Association meeting next month, will "have a big impact on Alzheimer's disease," said Dr. Daniel Skovronsky, founder of the company.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI